The Voice of China, ASCO 2019

The Voice of China, ASCO 2019


     
    Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicenter randomized controlled trial

    Abstract No: 6004
    Author: Prof. Mingyuan Chen (Sun Yat-Sen University Cancer Center, Guangzhou, China)
    Video Link: Watch Video
     
     

    Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial

    Abstract No: 6003
    Corresponding Author: Prof. Jun Ma (Sun Yat-Sen University Cancer Center, Guangzhou, China)
    First Author: Prof. Yuan Zhang (Sun Yat-Sen University Cancer Center, Guangzhou, China)
    Video Link: Watch Video

     

    Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study

    Abstract No: 7004
    Corresponding Author: Prof. Jianxiang Wang (Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China)
    First author: Prof. Li Zhang (State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China)

     
     

    S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial

    Abstract No: 4017
    Author: Prof. Ruihua Xu (Sun Yat-Sen University Cancer Center, Guangzhou, China)

     
     
     

     
    Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study

    Abstract No: 1001
    Author: Prof. Zefei Jiang (The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China)
     
     
     

    Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4)

    Abstract No: 7504
    Corresponding Author: Prof. Jianyong Li (Jiangsu Province Hospital, Nanjing, China)
    First Author: Prof. Rong Tao (Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China)